[HTML] frontiersin.org

[HTML][HTML] Quantitative Evaluation of 18F-Flutemetamol PET in Patients With Cognitive Impairment and Suspected Alzheimer's Disease: A Multicenter Study

H Matsuda, K Ito, K Ishii, E Shimosegawa… - Frontiers in …, 2021 - frontiersin.org
Background: In clinical practice, equivocal findings are inevitable in visual interpretation of
whether amyloid positron emission tomography (PET) is positive or negative. It is therefore …
被引用次数：27 相关文章

Quantitative Evaluation of 18F-Flutemetamol PET in Patients With Cognitive Impairment and Suspected Alzheimer's Disease: A Multicenter Study

H Matsuda, K Ito, K Ishii, E Shimosegawa… - Frontiers in …, 2021 - cir.nii.ac.jp
抄録< jats: p>< jats: bold> Background:</jats: bold> In clinical practice, equivocal findings
are inevitable in visual interpretation of whether amyloid positron emission tomography …

Quantitative Evaluation of 18F-Flutemetamol PET in Patients With Cognitive Impairment and Suspected Alzheimer's Disease: A Multicenter Study

H Matsuda, K Ito, K Ishii, E Shimosegawa… - Frontiers in …, 2021 - pure.fujita-hu.ac.jp
Background: In clinical practice, equivocal findings are inevitable in visual interpretation of
whether amyloid positron emission tomography (PET) is positive or negative. It is therefore …
[HTML] frontiersin.org

[HTML][HTML] Quantitative Evaluation of 18F-Flutemetamol PET in Patients With Cognitive Impairment and Suspected Alzheimer's Disease: A Multicenter Study

H Matsuda, K Ito, K Ishii, E Shimosegawa… - Frontiers in …, 2021 - frontiersin.org
Background: In clinical practice, equivocal findings are inevitable in visual interpretation of
whether amyloid positron emission tomography (PET) is positive or negative. It is therefore …

Quantitative Evaluation of 18F-Flutemetamol PET in Patients With Cognitive Impairment and Suspected Alzheimer's Disease: A Multicenter Study

H Matsuda, K Ito, K Ishii… - Frontiers in …, 2021 - pubmed.ncbi.nlm.nih.gov
Background: In clinical practice, equivocal findings are inevitable in visual interpretation of
whether amyloid positron emission tomography (PET) is positive or negative. It is therefore …

Quantitative Evaluation of 18F-Flutemetamol PET in Patients With Cognitive Impairment and Suspected Alzheimer's Disease: A Multicenter Study.

H Matsuda, K Ito, K Ishii, E Shimosegawa… - Frontiers in …, 2020 - europepmc.org
Background: In clinical practice, equivocal findings are inevitable in visual interpretation of
whether amyloid positron emission tomography (PET) is positive or negative. It is therefore …
[HTML] nih.gov

[HTML][HTML] Quantitative Evaluation of 18F-Flutemetamol PET in Patients With Cognitive Impairment and Suspected Alzheimer's Disease: A Multicenter Study

H Matsuda, K Ito, K Ishii, E Shimosegawa… - Frontiers in …, 2020 - ncbi.nlm.nih.gov
Background: In clinical practice, equivocal findings are inevitable in visual interpretation of
whether amyloid positron emission tomography (PET) is positive or negative. It is therefore …
[PDF] researchgate.net

[PDF][PDF] Quantitative Evaluation of 18 F-Flutemetamol PET in Patients With Cognitive Impairment and Suspected Alzheimer's Disease: A Multicenter Study

G Yener, A Bokde, R Duara, H Matsuda, H Matsuda… - researchgate.net
Background: In clinical practice, equivocal findings are inevitable in visual interpretation of
whether amyloid positron emission tomography (PET) is positive or negative. It is therefore …

Quantitative Evaluation of 18F-Flutemetamol PET in Patients With Cognitive Impairment and Suspected Alzheimer's Disease: A Multicenter Study

H Matsuda, K Ito, K Ishii, E Shimosegawa… - Frontiers in …, 2021 - pure.fujita-hu.ac.jp
Background: In clinical practice, equivocal findings are inevitable in visual interpretation of
whether amyloid positron emission tomography (PET) is positive or negative. It is therefore …